Genotype and phenotype of NAT2 and the occurrence of adverse drug reactions in Mexican individuals to an isoniazid-based prophylactic chemotherapy for tuberculosis

Bravo,

doi:10.3892/mmr_00000044

Cited by 5 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biehl et al (6,14) reported that neuropathy developed in 44.0% of patients receiving high-dose isoniazid and in 2.0% of those receiving low doses. In addition to the dose of isoniazid, factors such as patients' nutritional status and the rate of acetylation also increase the risk of neuropathy (15)(16)(17)(18). With the effect of all these factors, an increased blood concentration of isoniazid raises the drug's sideeffect potential (7,(19)(20)(21).…”

Section: Discussionmentioning

confidence: 99%

The Effects of Pyridoxine on Retinal Nerve Fiber Layer in Tuberculous Treatment

Fındık

Gümüş

Okutucu

et al. 2019

Düzce Tıp Fakültesi Dergisi

View full text Add to dashboard Cite

Aim: Ethambutol and isoniazid, two of the main drugs used in the treatment of tuberculosis, can lead to optic neuropathy. Optical coherence tomography (OCT) is a non-invasive, repeatable, high resolution imaging technique used in the diagnosis and follow-up of optic nerve diseases. The purpose of this study was to investigate the effect of pyridoxine added to antituberculous therapy on retinal nerve fiber layer (RNFL) thickness and the effectiveness of OCT in the early diagnosis and monitoring of optic neuropathy. Material and Methods: Twenty four patients diagnosed with pulmonary or non-pulmonary tuberculosis were included in the study. Patients divided into two groups. One group received antituberculous therapy alone, and the other group received 50 mg pyridoxine in addition to antituberculous therapy. RNFL thickness in both eyes was measured using OCT before treatment and 2-month after treatment. Results: The change in the second month of treatment according to baseline in terms of average RNFL thicknesses in the right eyes, showed a statistically significant difference between the groups using and not using pyridoxine (p=0,038). However, there was no significant difference in the left eyes in terms of RNFL thickness in any of the quadrants between the groups. Conclusion: Despite a decrease in RNFL thickness in patients receiving antituberculous therapy alone, no change in RNFL thickness occurred in patients receiving pyridoxine in addition to antituberculous therapy. We think that early ototoxicity can be detected with RNFL thickness measurement using OCT in asymptomatic patients and that the addition of pyridoxine to antituberculous therapy prevents ototoxicity.

show abstract

Section: Discussionmentioning

confidence: 99%

The Effects of Pyridoxine on Retinal Nerve Fiber Layer in Tuberculous Treatment

Fındık

Gümüş

Okutucu

et al. 2019

Düzce Tıp Fakültesi Dergisi

View full text Add to dashboard Cite

show abstract

“…It is surprising that there was no statistically significant difference in the incidence of polyneuropathy between the NAT2 genotype-guided treatment and the standard treatment group (Diaz-Molina et al. 2008 ). This result, and the fact that in some studies no association was found between the genotype or phenotype and the incidence of INH-related adverse reactions (Azuma et al.…”

Section: Discussionmentioning

confidence: 99%

Isoniazid‐induced polyneuropathy in a tuberculosis patient – implication for individual risk stratification with genotyping?

et al. 2015

View full text Add to dashboard Cite

BackgroundDevelopment of polyneuropathy (PNP) under treatment for tuberculosis (TB), including isoniazid (INH), is a highly relevant adverse drug effect. The NAT2 acetylation status is a predictor of potential toxic effects of INH. The question as to whether individual risk stratification by genotyping is useful to avoid suffering of patients and to lower costs for the health care system is of considerable clinical importance.Case PresentationAfter drug treatment for TB, including INH, a 23-year-old man developed severe PNP. During the treatment, laboratory results have been indicating incipient liver and renal injury. Later, molecular genetic analyses were performed and revealed a variation in the NAT2 gene and the c1/c2 genotype of the CYP2E1 gene, both described to contribute to an elevated risk for anti-tuberculostatic-induced liver damages (ATIL).ConclusionThe combination of metabolizer genotypes should be taken into account as a cause for toxic effects and the development of PNP. Individual genotyping, performed before medication or at least if an elevation of liver parameters is observed, may reduce the risk of severe cases of PNP by early adjustment of treatment. Our case study indicates that evaluation of individual risk stratification with systematic pharmacogenetic genotyping of metabolizer gene combinations in the context of TB treatment should be addressed in clinical studies with larger cohorts.

show abstract

N-acetyltransferase 2 enzyme genotype–phenotype discordances in both HIV-negative and HIV-positive Nigerians

Kotila¹,

Fawole

Olopade

et al. 2019

Pharmacogenetics and Genomics

View full text Add to dashboard Cite

Background: The N-acetyltransferase 2 (NAT2) enzyme has been understudied in Nigerians including genotype-phenotype association studies. Objective: Study objective was NAT2 haplotype identification and genotype-phenotype investigations in HIV-positive and HIV-negative Nigerians. Method: Phenotypes included self-reported sulphonamide hypersensitivity survey, experimental and computational NAT2 phenotyping. NAT2 gene was amplified via polymerase chain reaction. Gene sequencing employed ABI 3730 and Haploview 4.2 for haplotype reconstruction. Genotypephenotype analyses used Chi square p-value and odds ratio with 95% confidence interval. Results: Self-reported sulphonamide hypersensitivity revealed prevalence of 3.1% and 12.4% in HIV-positive and HIV-negative Nigerians respectively. NAT2 genetic variants 191G>A, 282C>T, 341T>C, 481C>T, 590G>A, 803A>G and 857 G>A were not significantly different between both groups (OR 0.87 95%CI 0.54-1.38 P = 0.55). Nine haplotypes: NAT2*4, NAT2*12A, NAT2*13A, NAT2*5B, NAT2*6A, NAT2*7B, NAT2*5C, NAT2*14B and NAT2*14A had frequencies > 1% while NAT2*12B had 1.1% in HIV-positive and 0.4% in HIV-negative group. Overall, slow acetylator haplotypes made up 68%. NAT2*12 signature SNP (sSNP) was in high linkage

show abstract

Genotype and phenotype of NAT2 and the occurrence of adverse drug reactions in Mexican individuals to an isoniazid-based prophylactic chemotherapy for tuberculosis

Cited by 5 publications

References 33 publications

The Effects of Pyridoxine on Retinal Nerve Fiber Layer in Tuberculous Treatment

The Effects of Pyridoxine on Retinal Nerve Fiber Layer in Tuberculous Treatment

Isoniazid‐induced polyneuropathy in a tuberculosis patient – implication for individual risk stratification with genotyping?

N-acetyltransferase 2 enzyme genotype–phenotype discordances in both HIV-negative and HIV-positive Nigerians

Contact Info

Product

Resources

About